Impact Interview: Darren Crowder, Founder and CEO of Enbodie

Can you introduce yourself and tell us about your role?

I’m Darren Crowder, founder and CEO of Enbodie — an agentic AI-driven preventative health platform that turns everyday smartphones (6.1 billion of them) into a team of clinical-grade health experts for your skin, eyes, gut and wider wellness systems, across all ethnicities, genders and historically underserved communities.

After more than three decades leading global businesses at SAP, Microsoft, BEA Systems and TIBCO, I stepped away from big tech to focus on a problem that is both personal and systemic: how little our health, beauty and wellness ecosystems understand real, diverse bodies, their daily exposures, and the environments they live in.

Multiple bouts of COVID changed my taste, skin and smell, and showed me first-hand how often clinicians and brands treat symptoms in isolation instead of connecting products, microbiomes and lived experience. Earlier in life, losing a friend to a missed brain tumour, and later having my own heart arrhythmia dismissed despite clear data from my watch, underlined how urgently we need health systems that predict and prevent rather than react and hope.

My driving purpose is to leave a measurable, positive mark on human health and the environment by making safer choices the default for billions of people — personal care genuinely harmonised with planetary care.

Enbodie starts by decoding the gut, skin and ocular axis, while cross-checking the daily products and ingredients you use against clinical toxicology, margins of safety and cumulative exposure. At the heart of this is the Microbial Mantle — a proven, clinically developed framework that treats the gut, skin and ocular surface as one living shield. This allows our AI to spot when a single preservative in a foundation is driving gritty eyes, bloating and rosacea together, rather than as three separate problems.

Powered by our living data intelligence layer, ELI, and our visual co-pilot, EVI, we build secure digital twins and AI agents that remember context, learn over time, and find outlier and anomaly data points — grounding every recommendation in ESG-aware choices, so that each small decision in someone’s routine can protect both their health and the world they pass on.

How did your company come about, and what was the motivation behind it?

What motivates me most is the gap between what is technically possible and what people — and the planet — actually experience in their everyday health and personal care.

We have 6.1 billion smartphones we can reach, advanced AI, and decades of toxicology, climate and microbiome science. Yet the average person still uses 100–200 ingredients a day without any clear sense of how safe they are for their body or for the ecosystems those products touch. Meanwhile, beauty and personal care alone generate around 120 billion units of mostly single-use packaging every year — a flow of plastic, cardboard and contaminated wastewater that simply cannot continue.

We see that not just as a health problem, but as an ESG failure that undermines several of the UN Sustainable Development Goals we align to, from good health and gender equality through to clean water, responsible consumption and climate action.

Enbodie came about as a response to that systemic blind spot. In our early work, we kept seeing the same patterns: products that looked “safe” on paper but drove hidden cumulative exposures; routines that harmed melanin-rich and gender-diverse users disproportionately; and supply chains with beautiful marketing and very thin evidence. Clinicians were treating thousands of patients with gut, skin and eye issues that traced back to the same ingredients and environmental triggers. It became clear we needed an intelligence layer that could link personal health, product safety and environmental impact in one view.

My motivation in building Enbodie is to make that linkage operational. I want your phone to help you avoid harm before your body or the environment pays the price, and to make safer, lower-impact choices the effortless default — so every routine quietly advances both human health and the ESG goals we say we care about, with personal care genuinely harmonised with planetary care.

Can you describe your company’s mission and values?

Put simply: we exist to make safer choices the default for billions of people, with personal care genuinely harmonised with planetary care.

That mission shows up in three ways.

First, we treat the body as one connected system — gut, skin and eyes — and focus on early signals, not late-stage symptoms. Prevention for us means identifying hidden harms, connecting gritty eyes, bloating and rosacea back to shared triggers in products, routines and environments, and intervening before they become diagnoses.

Second, we design for inclusion by default. Our intelligence is melanin-aware, gender-aware, socio-culturally aware and values-aware — correcting the reality that most medical devices and datasets over-represent older, white, male bodies. We are explicit about serving historically underserved communities, not treating them as edge cases, and we align this work with UN SDGs around health, gender equality and reduced inequalities.

Third, we embed ESG into the core of the platform. Through ELI (Enbodie Living Intelligence), our living data ontology, and the Enbodie Index, we quantify safety, environmental impact, ethical sourcing, transparency and ingredient integrity — helping partners move from “safe until proven toxic” to evidence-graded, responsible supply chains. Our aim is to turn 120 billion units of largely single-use beauty packaging, contaminated wastewater and high-risk chemical exposure into a system of safer swaps, regenerative inputs and traceable, lower-impact products.

Underpinning all of this are a few simple values: prevention over reaction; inclusion over averages; evidence over marketing; transparency over greenwashing; and long-term planetary health over short-term convenience.

What are some of the most pressing social issues that your company is working to address through its technology?

1. Preventable, exposure-driven illness

Environmental exposures explain far more premature death risk than genetics, yet people are unknowingly exposed to around 120 high-risk chemicals daily, with PFAS “forever chemicals” found in 97% of the population’s blood.

Groundbreaking research from the UK Dementia Research Institute reveals that Parkinson’s disease often starts in the gut, not the brain. Toxic proteins can appear in gut tissue decades before reaching the brain, with early warning signs like constipation and bloating preceding diagnosis by years. Gut inflammation and “leaky gut” create conditions that allow these toxic proteins to spread via the vagus nerve into the brain.

Enbodie detects harmful ingredients, cumulative exposures and risky combinations across your daily routine, then recommends safer alternatives before these exposures cascade into chronic gut–skin–eye disease, or contribute to devastating neurodegenerative pathways.

2. Health inequality and fragmented care

Traditional healthcare treats symptoms in isolation — dermatology separated from toxicology, gut health disconnected from skin conditions, ocular issues divorced from cosmetic exposures. This fragmentation disproportionately harms underserved communities.

87% of medical devices are trained on white males aged 60–85, resulting in 34.7% diagnostic error rates for darker skin tones. Women and people of colour face longer NHS dermatology wait times, higher misdiagnosis rates, and disproportionate toxic chemical exposure — particularly Black women through beauty products marketed specifically to them. The average person uses 12 products daily containing 168 ingredients, with zero real-time triage connecting those exposures to symptoms appearing across multiple body systems.

Enbodie democratises consultant-grade intelligence by treating the gut–ocular–skin axis as one integrated Microbial Mantle, making clinical-quality preventative health accessible to everyone with a smartphone, regardless of ethnicity, gender, geography or income.

3. Environmental collapse and supply chain opacity

The beauty and wellness industry generates 120 billion units of single-use packaging and 10.4 million tonnes of contaminated wastewater annually, yet operates under “safe until proven toxic” with minimal transparency about ingredient sourcing, worker welfare or ecological impact. PFAS persist in soil, water and bodies indefinitely, while regulatory bans lag years behind science. Consumers want sustainable choices but lack tools to decode greenwashing or trace products from soil to skin.

Enbodie’s proprietary Index synthesises toxicology, regenerative agriculture metrics, fair labour practices, carbon footprint and supply chain traceability into one continuously updated score. We’ve delivered 80% ESG improvement per user and an average of £60 monthly savings by eliminating harmful duplicates — building the operating system for product truth that holds industry accountable while rewarding genuine innovation.

How does your company measure the impact of its work in creating positive change?

We measure impact across three interconnected dimensions: individual health outcomes, collective behaviour change, and systemic industry accountability.

Individual health outcomes: Our 500+ real-world participants provide quantifiable proof. 100% discovered and eliminated harmful ingredients they didn’t know they were using. Each user averaged 3.4 safer product swaps, achieving 80% ESG improvement in their routines while saving £60 monthly by eliminating duplicate exposures.

We operationalise the Microbial Mantle framework — developed by Dr Rachna Murthy and proven internationally across real-world patients — tracking skin barrier function, ocular surface health, digestive symptoms and inflammatory markers. Users typically see measurable improvements: by day 7, ocular grit resolves; by day 14, bloating subsides; by day 28, rosacea fades and skin glow returns.

Collective intelligence and prevention at scale: Our living intelligence framework (ELI) learns from every scan, building synthetic cohorts and real-world evidence that traditional trials cannot capture. We’ve mapped 111 million products and 45 million toxicology data points, and we’re currently expanding into image-based analysis. Our MVP includes a vote-up system where consumers prioritise the features they want built, while our community discusses new research from our constant learnings. We deploy R&D agentic AI agents across our platform to continuously learn from the latest global research and understand new rules from regulatory commissions in different countries — creating epidemiological signals that predict which ingredients trigger flares before regulatory bodies act.

Industry accountability and systemic change: We align with nine UN Sustainable Development Goals and are pursuing B-Corp certification, while implementing ISO 13485 quality management systems — the same clinical-grade standard NHS Trusts require. We measure enterprise adoption: how many brands reformulate based on our cumulative exposure intelligence, how many legal teams use our causation data to avoid litigation, and how many insurers adjust policies based on our risk predictions. Our 84% UK IPO patent pass rate and 12 pending patents create defensible IP, forcing transparency standards industry-wide and building regulatory scaffolding that makes unsafe products commercially unviable — turning prevention from aspiration into infrastructure.

In your opinion, what impact will technology have in creating a better future?

Technology’s greatest impact will come from democratising expertise and making prevention the default, not the luxury.

AI can now scan millions of images trained on real people’s health, analyse billions of data points, and connect dots humans simply cannot see — spotting outlier patterns, anomalies and causation pathways that remain invisible to individual clinicians. This means finding cures quicker, predicting disease before symptoms manifest, and shifting from reactive treatment to true prevention at population scale.

For too long, advanced healthcare, environmental intelligence and regulatory-grade safety data have been locked behind paywalls, postcodes and privilege. Technology — specifically agentic AI operating at the edge on devices people already own — can flip that equation entirely.

The future I’m building towards is one where your smartphone becomes your first line of defence. Where a parent in Aberdeen has the same real-time toxicology intelligence as a Harley Street consultant. Where melanin-rich skin receives the same diagnostic accuracy as the white male cohorts that trained 87% of medical devices. Where gut health, skin conditions and ocular symptoms are connected as one integrated system — the Microbial Mantle — rather than fragmented across three specialists with 14-week average wait times.

But here’s the critical insight: people consistently say they want to support sustainability, yet when eco-friendly products cost more, wallets choose cheaper options even when values don’t align. We tested this directly. By optimising our algorithms to prioritise ESG-aligned products and safer ingredients that are also cheaper, we unlocked systemic behaviour change. The data proved it unequivocally — users achieved 80% better ESG footprints while saving £60 monthly. They told us they’d switched products and kept switching. When doing good costs less than doing harm, adoption becomes inevitable.

Technology will create a better future by making invisible harms visible, supply chains transparent, and sustainable choices the economically rational default. But it must be built with equity, transparency and planetary health as non-negotiable design principles — not features bolted on later.

What advice do you have for other companies looking to use tech for good and positively impact the world?

Start with the problem, not the technology — and don’t copy others. Having competition is a good thing; don’t let it put you off. It means there’s a market, and your idea might totally disrupt and improve it.

Too many companies build impressive solutions searching for problems to solve, or worse, chase competitors without understanding why those solutions exist. Do the due diligence. Understand your target market deeply. Spend time with the communities you’re trying to serve. We started with: “Let’s use everyday technology for purpose. There are billions of smartphones, PCs and tablets. Billions of people suffering unnecessarily — how do we impact this? Let’s take advantage of our connected world, reach consumers directly, empower them, and uplift health globally.” Aim not just for the buzzword of 2026, which is Longevity, but Quality Longevity in terms of your life.

We also continuously hear how economically health is crippling countries — so much money globally for governments. Many countries are jealous of the NHS system, for example, and many simply can’t afford it. So how can we contribute to reducing this burden? How can we scale it? What could we bring to the market?

Starting with the gut–skin–ocular triage axis as AI agents is just the beginning. It’s important to test your thesis as you go along, so that’s what we’re doing. We iterate. We listen to our users. Let me say this: don’t be like Apple. I love Apple products, but they do a poor job of listening to customers properly. Make your customers fans.

Have integrity and values from day one, and stick to them. One of our core mandates is simple: we aren’t here to promote any specific brand if it doesn’t fit the efficacy we expect and the integrity we demand — in other words, the change we want for the world. Think as if this were your family involved. Think with integrity.

For us, it was simple: products must contain no harmful ingredients and do what they say on the tin. We’re independent of all and can’t be bought — not via advertising, affiliate schemes, or other commercial pressures. Our business model isn’t based on that. We’re the Switzerland of health: neutral, evidence-based, and incorruptible.

Make impact measurable from day one. We tracked every data point from our first 500 users — from day one. That’s how we learnt and improved, and that’s why people love us and are impressed by our journey. Our focus on ingredients eliminated, safer swaps, ESG improvements, cost savings and health outcomes. This rigour attracts serious capital and clinical partnerships.

Build for the underserved. We designed for gender-diverse, melanin-rich skin, historically underserved communities, and 6.1 billion smartphone users.

Align economics with values, or behaviour won’t change. We proved that ESG-aligned, safer products that cost less unlock systemic change: 80% better footprints while users save money.

Finally, build regulatory readiness into your DNA. We implemented ISO 13485, pursued B-Corp certification, and aligned with nine UN SDGs before scaling. Don’t do the easy stuff first.

What stands out in this conversation is the refusal to treat human health and planetary health as separate problems. For decades, the wellness industry has done exactly that — selling products that promise individual benefit while quietly contributing to environmental harm, cumulative chemical exposure, and supply chains built on opacity. Enbodie’s work is a quiet rejection of that bargain.

Equally notable is the inclusion thesis. The fact that 87% of medical devices are trained on a single demographic, and that diagnostic error rates rise sharply for darker skin tones, is not a marginal data point — it is a structural failure of who modern medicine was designed for. Building intelligence that is melanin-aware, gender-aware, and culturally aware by default is not a feature; it is a corrective.

If Enbodie’s central insight holds — that safer choices, better data and lower environmental impact can be made the economically rational default rather than the premium option — then the implications stretch well beyond beauty and personal care. It is a reminder that the tech-for-good companies most likely to drive systemic change are the ones rebuilding the economics of doing the right thing, not just the ethics of it.